Robert Iannone is CMO & VP at Jazz Pharmaceuticals plc (JAZZ). They have made 2 open-market trades across 1 company since 2022, most recently 2026-08-27.
CIK 0001737329
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JAZZ | 65,686 | $13.8M |
Shares reported on the most recent Form 4, priced at the 2026-08-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JAZZ | SELL · 10b5-1 | 2026-08-27 | 2026-08-31 | $249.70 | $19.2M | -2.6% | -8.3% | — |
| JAZZ | SELL · 10b5-1 | 2025-11-17 | 2025-11-19 | $168.26 | $2.4M | -5.4% | -5.3% | -4.7% |
| JAZZ | SELL | 2025-03-10 | 2025-03-12 | $138.41 | $665K | +4.6% | -26.0% | -16.8% |
| JAZZ | SELL · 10b5-1 | 2025-03-07 | 2025-03-07 | $138.43 | $1.7M | +2.8% | -22.6% | -21.3% |
| JAZZ | SELL | 2022-12-09 | 2022-12-13 | $151.54 | $559K | +2.5% | +2.8% | -12.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.